PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9777524

A rapid (20 h) solid screening medium for detecting methicillin-resistant Staphylococcus aureus.

P L Perry·G W Coombs·J D Boehm·J W Pearman
View original source ↗Export metadata ↓

Abstract

Methicillin aztreonam mannitol salt agar is a sensitive and reliable solid screening medium for detecting methicillin-resistant Staphylococcus aureus (MRSA). With this medium an incubation period of only 20 h is sufficient to either produce visible colonies of MRSA or to exclude MRSA (no staphylococcal colonies). Coagulase testing (requiring a further 6 h) enables coagulase-positive isolates to be provisionally reported as 'possible MRSA' 26-30 h after the swabs were collected. The medium supports growth of intrinsically resistant staphylococci including low-expression-class MRSA (methicillin minimum inhibitory concentration (MIC) 8-16 mg/L), but methicillin susceptible staphylococci and beta-lactamase hyperproducers are suppressed.

Explore related subjects

Carrier StateCulture MediaHumansMethicillinMethicillin ResistanceStaphylococcal InfectionsStaphylococcus aureusJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P L Perry, G W Coombs, J D Boehm, J W Pearman. 1998. A rapid (20 h) solid screening medium for detecting methicillin-resistant Staphylococcus aureus.. https://doi.org/10.1016/s0195-6701(98)90027-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age.

To estimate the efficacy in The Gambia (West Africa) of infant hepatitis B vaccination against infection and carriage with the virus at the age of 9 years. The HBV status of 9-year old children vaccinated in infancy was compared to that of unvaccinated children of the same age. Eight percent of the vaccinated children had been infected by HBV compared to 50% of the unvaccinated control group; HBV carrier status was 0.6 and 10% respectively, resulting in a vaccine efficacy of 83% against infection and of 95% against chronic carriage. The results show that infant vaccination provides a high level of protection at the age of nine years against both HBV infection and chronic carrier status and no booster dose of vaccine is required in the first decade. These findings support the WHO recommendation for the introduction of HBV vaccination into the Expanded Programme on Immunization in Africa.

Carrier State↗